These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38202107)

  • 21. Use of Cidofovir for Cytomegalovirus Disease Refractory to Ganciclovir in Solid Organ Recipients.
    Bonatti H; Sifri CD; Larcher C; Schneeberger S; Kotton C; Geltner C
    Surg Infect (Larchmt); 2017; 18(2):128-136. PubMed ID: 27849440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients.
    Jorgenson MR; Descourouez JL; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2021 Aug; 23(4):e13693. PubMed ID: 34309158
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Successful treatment with foscarnet for ganciclovir-resistant cytomegalovirus infection in a kidney transplant recipient: A case report.
    Iwami D; Ogawa Y; Fujita H; Morita K; Sasaki H; Oishi Y; Higuchi H; Hatanaka K; Shinohara N
    Nephrology (Carlton); 2016 Jul; 21 Suppl 1():63-6. PubMed ID: 26970406
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature.
    Corcione S; Lupia T; Vita D; Sidoti F; Zanotto E; Solidoro P; Biancone L; Costa C; Balagna R; De Rosa FG
    Transplant Rev (Orlando); 2024 Dec; 38(4):100873. PubMed ID: 39178643
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
    Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
    Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited sampling strategy for the estimation of the area under the concentration-time curve for ganciclovir in Chinese adult renal allograft recipients.
    Rui WB; An HM; Shao K; Zhai XH; Lu JQ; Hu SS; Chen B; Zhou PJ
    Eur J Clin Pharmacol; 2019 May; 75(5):677-686. PubMed ID: 30643927
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus Infection in Pediatric Renal Transplantation and the Impact of Chemoprophylaxis With (Val-)Ganciclovir.
    Höcker B; Zencke S; Krupka K; Fichtner A; Pape L; Dello Strologo L; Guzzo I; Topaloglu R; Kranz B; König J; Bald M; Webb NJ; Noyan A; Dursun H; Marks S; Yalcinkaya F; Thiel F; Billing H; Pohl M; Fehrenbach H; Bruckner T; Tönshoff B
    Transplantation; 2016 Apr; 100(4):862-70. PubMed ID: 26736017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low-dose valganciclovir for cytomegalovirus prophylaxis in intermediate-risk liver transplantation recipients.
    Khan S; Sullivan T; Ali M; Dunn D; Patel G; Huprikar S
    Liver Transpl; 2018 May; 24(5):616-622. PubMed ID: 29500912
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Suppression of CMV Infection with Letermovir in a Kidney Transplant Patient.
    Koepf US; Klehr HU; Eis-Huebinger AM; Aldabbagh S; Strassburg CP; Boes D; Lutz P
    Eur J Case Rep Intern Med; 2020; 7(7):001622. PubMed ID: 32665929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
    Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
    JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resistant cytomegalovirus in intestinal and multivisceral transplant recipients.
    Timpone JG; Yimen M; Cox S; Teran R; Ajluni S; Goldstein D; Fishbein T; Kumar PN; Matsumoto C
    Transpl Infect Dis; 2016 Apr; 18(2):202-9. PubMed ID: 26853894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
    Chen TT; David AP; Barthelmess EK; MacBrayne CE
    Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.
    Isada CM; Yen-Lieberman B; Lurain NS; Schilz R; Kohn D; Longworth DL; Taege AJ; Mossad SB; Maurer J; Flechner SM; Mawhorter SD; Braun W; Gordon SM; Schmitt SK; Goldman M; Long J; Haug M; Avery RK
    Transpl Infect Dis; 2002 Dec; 4(4):189-94. PubMed ID: 12535261
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Resistant Cytomegalovirus Infection in Solid-organ Transplantation: Single-center Experience, Literature Review of Risk Factors, and Proposed Preventive Strategies.
    Majeed A; Latif A; Kapoor V; Sohail A; Florita C; Georgescu A; Zangeneh T
    Transplant Proc; 2018 Dec; 50(10):3756-3762. PubMed ID: 30586840
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GCV/VCVG prophylaxis against CMV DNAemia in pediatric renal transplant patients: A systematic review and meta-analysis.
    Chatani B; Glaberson W; Nemeth Z; Tamariz L; Gonzalez IA
    Pediatr Transplant; 2019 Sep; 23(6):e13514. PubMed ID: 31210393
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low dose valganciclovir as cytomegalovirus prophylaxis in post-renal transplant recipients induced with alemtuzumab: A single-center study.
    Korneffel K; Mitro G; Buschor K; Rees M; Ortiz J
    Transpl Immunol; 2019 Oct; 56():101226. PubMed ID: 31344441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Dynamics of Cytomegalovirus UL97 Ganciclovir Resistance Mutations in Transplant Recipients Detected by Next-Generation Sequencing.
    Lodding IP; Jørgensen M; Bennedbæk M; Kirkby N; Naegele K; Gustafsson F; Perch M; Rasmussen A; Sengeløv H; Sørensen SS; Hirsch HH; Lundgren JD
    Open Forum Infect Dis; 2021 Oct; 8(10):ofab462. PubMed ID: 34660835
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipients.
    Fayek SA; Mantipisitkul W; Rasetto F; Munivenkatappa R; Barth RN; Philosophe B
    HPB (Oxford); 2010 Dec; 12(10):657-63. PubMed ID: 21083790
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
    Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
    Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease.
    Kotton CN; Kamar N
    Infect Dis Ther; 2023 Feb; 12(2):333-342. PubMed ID: 36583845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.